Market news
On August 4, Certara (NASDAQ:CERT) reported second-quarter 2026 results that told two different stories at once. Software revenue climbed 4% to $48.8 million, and bookings for that segment jumped 9%, yet the company swung to a $6.1 million net loss just a year after posting a small profit. Layered on top of a completed divestiture, […]
Detailed price information for Certara Inc (CERT-Q) from The Globe and Mail including charting and trades.
Detailed price information for Certara Inc (CERT-Q) from The Globe and Mail including charting and trades.
Detailed price information for Certara Inc (CERT-Q) from The Globe and Mail including charting and trades.
Detailed price information for Certara Inc (CERT-Q) from The Globe and Mail including charting and trades.
Software revenue hit 53% of total as AI-assisted code boosted development 65% year over year.
Moby summary of Certara, Inc.'s Q2 2026 earnings call
Certara (NASDAQ:CERT) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by Benzinga APIs. For
Certara (CERT) shares were down more than 13% in early Tuesday trading after the company posted Q2 r
Certara (CERT) delivered earnings and revenue surprises of -20.00% and -5.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Certara (NASDAQ:CERT) reported second-quarter 2026 revenue of $93.3 million, up 1% year over year, as software growth offset a decline in services revenue. Management reaffirmed its full-year revenue outlook while outlining further changes to its commercial organization, cost structure and artificia
Motley Fool Press Release.
Detailed price information for Certara Inc (CERT-Q) from The Globe and Mail including charting and trades.
Certara has announced a partnership with NVIDIA to enhance its AI platform for drug discovery and development by incorporating the NVIDIA BioNeMo Agent Toolkit. This collaboration aims to unify Certara's biosimulation software, regulatory expertise, and datasets with AI-driven agents that provide specialized insights for life sciences. The toolkit enables AI agents to function autonomously, complementing biosimulation models and scientific expertise to accelerate the drug development process...
Partnership expands AI capabilities for drug developmentCertara, Inc. (NASDAQ:CERT) has announced a collaboration with Nvidia (NASDAQ:NVDA) to integrate the Nvidia BioNeMo Agent Toolkit into its artificial intelligence platform, bringing together Certara’s biosimulation technology, regulatory expertise and proprietary data with advanced agentic AI capabilities.
Nvidia expands its life sciences AI ecosystem through a Certara partnership and QwikAgents' entry into its developer program.
This is the newest page. Registered accounts read further back.